The lung as a privileged site for the beneficial actions of PGE2

Trends in Immunology

Volumn 25, Issue 1, 2004, Pages 40-46

  Vancheri, Carlo ^a   Mastruzzo, Claudio ^a   Sortino, Maria Angela ^a   Crimi, Nunzio ^a  

^a UNIVERSITY OF CATANIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AUTACOID; CHEMOKINE RECEPTOR CCR2; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 8; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MONOCYTE CHEMOTACTIC PROTEIN 1; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN E2; PROSTAGLANDIN SYNTHASE; PROSTANOID; THROMBOXANE A2; TRANSFORMING GROWTH FACTOR; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1;

ALLERGIC PNEUMONITIS; ANTIINFLAMMATORY ACTIVITY; ASTHMA; BRONCHODILATATION; BRONCHOSPASM; CYTOKINE PRODUCTION; DRUG EFFECT; DRUG MECHANISM; ENZYME INHIBITION; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; INFLAMMATORY DISEASE; LUNG DISEASE; LUNG FIBROSIS; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTE TRANSFER; NONHUMAN; PATHOGENESIS; PROSTAGLANDIN METABOLISM; PROSTAGLANDIN SYNTHESIS; PROTEIN FUNCTION; REGULATORY MECHANISM; REVIEW; SARCOIDOSIS; T LYMPHOCYTE; TISSUE REPAIR;

EID: 0346961783     PISSN: 14714906     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.it.2003.11.001     Document Type: Review

References (71)

1. Smith W.L., Langenbach R. Why there are two cyclooxygenase isozymes. J. Clin. Invest. 107:2001;1491-1495.
2. Smith W.L., et al. Cyclooxygenases: structural, cellular and molecular biology. Annu. Rev. Biochem. 69:2000;145-182.
3. Tilley S.L., et al. Mixed messages: modulation of inflammation and immune responses by prostaglandins and thromboxanes. J. Clin. Invest. 108:2001;15-23.
4. Harris S.G., et al. Prostaglandins as modulators of immunity. Trends Immunol. 23:2002;144-150.
5. Wilgus T.A., et al. Inhibition of ultraviolet light B-induced cutaneous inflammation by a specific cyclooxygenase-2 inhibitor. Adv. Exp. Med. Biol. 507:2002;85-89.
6. McCoy J.M., et al. The role of prostaglandin E2 receptors in the pathogenesis of rheumatoid arthritis. J. Clin. Invest. 110:2002;651-658.
7. Ozaki T., et al. Cyclooxygenase metabolites are compartmentalized in the human lower respiratory tract. J. Appl. Physiol. 62:1987;219-222.
8. Peskar B.M., et al. Role of cyclooxygenase-1 and -2, phospholipase C, and protein kinase C in prostaglandin-mediated gastroprotection. J. Pharmacol. Exp. Ther. 305:2003;1233-1238.
9. 2 in mice. J. Appl. Physiol. 88:2000;2214-2218.
10. Hartet T.V., et al. Prostaglandin E2 decrease allergen-stimulated release of prostaglandin D2 in airways of subject with asthma. Am. J. Respir. Crit. Care Med. 162:2000;637-640.
11. 2 on allergen-induced airway responses and airway inflammation. Am. J. Respir. Crit. Care Med. 159:1999;31-36.
12. Kita H.R.I., et al. Regulation of Ig-induced eosinophils degranulation by adenosine 3′ 5′- cyclic monophosphate. J. Immunol. 146:1991;2712-2718.
13. 2 on eicosanoid release by human bronchial biopsy specimen from normal and inflamed mucosa. Thorax. 51:1996;919-923.
14. Flamand N., et al. cAMP-mediated inhibition of 5-lipoxygenase translocation and leukotriene biosynthesis in human neutrophils. Mol. Pharmacol. 62:2002;250-256.
15. 4 production from dendritic cells via an IL-10-dependent mechanism. J. Immunol. 170:2003;139-146.
16. O'Byrne P.M. Exercise-induced bronchoconstriction: elucidating the role of leukotrienes and prostaglandins. Pharmacotherapy. 17:1997;31S-38S.
17. 4 synthase in bronchial biopsies from patients with aspirin-intolerant asthma. J. Clin. Invest. 101:1998;834-846.
18. Schafer D., et al. Dynamics of eicosanoids in peripheral blood cells during bronchial provocation in aspirin-intolerant asthmatics. Eur. Respir. J. 13:1999;638-646.
19. Picado C., et al. Cyclooxygenase-2 mRNA is downexpressed in nasal polyps from aspirin-sensitive asthmatics. Am. J. Respir. Crit. Care Med. 160:1999;291-296.
20. 4 excretion in aspirin-sensitive asthma. Am. J. Respir. Crit. Care Med. 153:1996;572-575.
21. 2 on this release from peripheral blood leukocytes in aspirin-induced asthmatic patients. Clin. Exp. Allergy. 31:2001;1615-1622.
22. Szczeklik A., et al. Relationship of inhibition of prostaglandin biosynthesis by analgesics to asthma attacks in aspirin-sensitive patients. BMJ. 1:1975;67-69.
23. Szczeklik A., Stevenson D.D. Aspirin-induced asthma: advances in pathogenesis and management. J. Allergy Clin. Immunol. 104:1999;5-13.
24. Szczeklik A., et al. Safety of a specific COX-2 inhibitor in aspirin-induced asthma. Clin. Exp. Allergy. 31:2001;219-225.
25. Gyllfors P., et al. Biochemical and clinical evidence that aspirin-intolerant asthmatic subjects tolerate the cyclooxygenase 2-selective analgesic drug celecoxib. J. Allergy Clin. Immunol. 111:2003;1116-1121.
26. Holgate S.T., et al. Roles of cysteinyl leukotrienes in airway inflammation, smooth muscle function, and remodeling. J. Allergy Clin. Immunol. 111:(Suppl. 1):2003;S18-S36.
27. Israel-Assayag E., et al. Blockade of T cell costimulation by CTLA4-Ig inhibits lung inflammation in murine hypersensitivity pneumonitis. J. Immunol. 163:1999;6794-6799.
28. Agostini C., et al. T-lymphocytes and cytokines in sarcoidosis. Curr. Opin. Pulm. Med. 8:2002;435-440.
29. Okazaki T., et al. Impairment of bleomycin-induced lung fibrosis in CD28-deficient mice. J. Immunol. 167:2001;1977-1981.
30. Larchè M., et al. The role of T lymphocytes in the pathogenesis of asthma. J. Allergy Clin. Immunol. 111:2003;450-463.
31. 2 and other cAMP-elevating agents modulate IL-2 and IL-2Rα gene expression at multiple levels. J. Immunol. 148:1992;2845-2852.
32. 2. J. Immunol. 152:1994;5703-5713.
33. Panettieri R.A., et al. Activation of cAMP-dependent pathways in human airways smooth muscle cells inhibits TNF-α-induced ICAM-1 and VCAM-1 expression of T lymphocyte adhesion. J. Immunol. 154:1995;2358-2365.
34. Pober J.S., et al. Elevated Cyclic AMP inhibits endothelial cell synthesis and expression of TNF-induced endothelial leukocyte adhesion molecule-1 and vascular cell adhesion molecule-1, but not intercellular adhesion molecule-1. J. Immunol. 150:1993;5114-5123.
35. 2 differentially modulates cytokine secretion profiles of human T helper lymphocytes. J. Immunol. 150:1993;5321-5329.
36. 2 inhibits production of Th1 lymphokines but not of Th2 lymphokines. J. Immunol. 146:1991;108-113.
37. Martin J.G., et al. The immunomodulatory actions of prostaglandin E2 on allergic airway responses in the rat. J. Immunol. 169:2002;3963-3969.
38. Peebles S.R. Jr, et al. Cyclooxygenase inhibition increases interleukin 5 and interleukin 13 production and airway hyperresponsiveness in allergic mice. Am. J. Respir. Crit. Care Med. 162:2000;676-681.
39. Peebles S.R. Jr, et al. Selective Cyclooxygenase-1 and -2 inhibitors each increase allergic inflammation and airway hyperresponsiveness in mice. Am. J. Respir. Crit. Care Med. 165:2002;1154-1160.
40. Gavett S.H., et al. Allergic lung responses are increased in prostaglandin H synthase-deficient mice. J. Clin. Invest. 104:1999;721-732.
41. Hart P.H. Regulation of the inflammatory response in asthma by mast cell products. Immunol. Cell Biol. 79:2001;149-153.
42. 2 in limiting lung mucosal Th2, but not Th1, responses to inhaled allergen. J. Immunol. 169:2002;5997-6004.
43. 2 signaling and cAMP elevation. Am. J. Respir. Cell Mol. Biol. 29:2003;537-544.
44. Saltzman L.E., et al. Modulation of collagen production by fibroblasts: effects of chronic exposure to agonists that increase intracellular cyclic AMP. Biochem. J. 204:1982;25-30.
45. 2 is a potent inhibitor of human interleukin-12 production. J. Exp. Med. 181:1995;775-779.
46. 2 and dexamethasone. Am. J. Respir. Cell Mol. Biol. 6:1992;75-81.
47. Rolfe M.W., et al. Expression and regulation of human pulmonary fibroblast-derived monocyte chemotactic peptide-1. Am. J. Physiol. 263:1992;L536-L545.
48. 2 and cAMP elevating drugs on GM-CSF release by cultured human airway smooth muscle cells. Am. J. Respir. Cell Mol. Biol. 24:2001;44-48.
49. Moore B.B., et al. GM-CSF regulates bleomycin-induced pulmonary fibrosis via a prostaglandin-dependent mechanism. J. Immunol. 165:2000;4032-4039.
50. -/- mice: implication for fibroproliferation. Am. J. Physiol. Lung Cell. Mol. Physiol. 284:2003;L1103-L1111.
51. 2. FEBS Lett. 400:1996;315-318.
52. 2 production in normal and fibrotic lung fibroblasts: potential implications for the evolution of the inflammatory process. Am. J. Respir. Cell Mol. Biol. 22:2000;628-634.
53. Vancheri C., et al. Normal human lung fibroblasts differently modulate interleukin-10 and interleukin-12 production by monocytes: implications for an altered immune response in pulmonary chronic inflammation. Am. J. Respir. Cell Mol. Biol. 25:2001;592-599.
54. 2 synthesis and suppression of fibroblast proliferation by alveolar epithelial cells is cyclooxygenase-2 dependent. Am. J. Respir. Cell Mol. Biol. 27:2002;752-758.
55. Moore B.B., et al. Protection from pulmonary fibrosis in the absence of CCR2 signaling. J. Immunol. 167:2001;4368-4377.
56. 2. Am. J. Physiol. Lung Cell. Mol. Physiol. 284:2003;L342-L349.
57. Gauldie J., et al. A new direction in the pathogenesis of idiopathic pulmonary fibrosis ? Respir. Res. 3:2002;1-3.
58. Selman M., et al. Idiopathic pulmonary fibrosis: prevailing and evolving hypothesis about its pathogenesis and implications for therapy. Ann. Intern. Med. 134:2001;136-151.
59. Davies D.E., et al. Asthma: the importance of epithelial mesenchimal communication in pathogenesis inflammation and the airway epithelium in asthma. Int. J. Biochem. Cell Biol. 34:2002;1520-1526.
60. Olman M.A., et al. Epithelial cell modulation of airway fibrosis in asthma. Am. J. Respir. Cell Mol. Biol. 28:2003;125-128.
61. Gray P.R., et al. Epithelial strips: an alternative technique for examining arachidonate metabolism in equine tracheal epithelium. Am. J. Respir. Cell Mol. Biol. 6:1992;29-36.
62. 2 and to express COX-2. J. Clin. Invest. 95:1995;1861-1868.
63. McAnulty R.J., et al. Indomethacin suppresses the anti-proliferative effects of transforming growth factor-β isoforms on fibroblast cell cultures. Biochem. J. 321:1997;639-643.
64. 2. Am. Rev. Respir. Dis. 144:1991;1080-1084.
65. Keerthisingam C.B., et al. Cyclooxygenase-2 deficiency results in a loss of the anti-proliferative response to transforming growth factor-β in human fibrotic lung fibroblasts and promotes bleomycin-induced pulmonary fibrosis in mice. Am. J. Pathol. 158:2001;1411-1422.
66. Bonner J.C., et al. Susceptibility of cyclooxygenase-2-deficient mice to pulmonary fibrogenesis. Am. J. Pathol. 161:2002;459-470.
67. Peters-Golden M., et al. Protection from pulmonary fibrosis in leukotriene-deficient mice. Am. J. Respir. Crit. Care Med. 165:2002;229-235.
68. 2 increases surfactant secretion via the EP1 receptor in rat alveolar type II cells. Eur. J. Pharmacol. 426:2001;21-24.
69. 2 regulates wound closure in airway epithelium. Am. J. Physiol. Lung Cell. Mol. Physiol. 280:2001;L421-L431.
70. 2 that regulate cellular immune responses in the mouse. J. Clin. Invest. 108:2001;1229-1235.
71. 2 suppresses chemokines production in human macrophages through the EP4 receptor. J. Biol. Chem. 277:2002;44147-44154.